Ignite Creation Date:
2024-10-26 @ 3:41 PM
Last Modification Date:
2024-10-26 @ 3:41 PM
Study NCT ID:
NCT06624098
Status:
RECRUITING
Last Update Posted:
None
First Post:
2024-10-01
Brief Title:
Early Transjugular Intrahepatic Portosystemic Shunt for Advanced Hepatocellular Carcinoma
Sponsor:
None
Organization:
None
Study Overview
Official Title:
Early Transjugular Intrahepatic Portosystemic Shunt for Advanced Hepatocellular Carcinoma With Main Trunk Portal Vein Tumor Thrombus Induced Gastrointestinal Bleeding a Multicenter Phase II Study
Status:
RECRUITING
Status Verified Date:
2024-10
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
No
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
Hepatocellular carcinoma HCC with main trunk portal vein tumor thrombus PVTT has poor prognosis The main lethiferous factor is the upper gastrointestinal hemorrhage by PVTT-related portal hypertension Studies have proven that early transjugular intrahepatic portosystemic shunt TIPS with 72 hours after acute variceal bleeding is effective
Detailed Description:
Portal hypertension by main trunk portal vein tumor thrombus PVTT is a severe disease Patients usually die of gastrointestinal hemorrhage rather than tumor progression It is vital to prevent the portal hypertension Transjugular intrahepatic portosystemic shunt TIPS is an effective method to alleviate the portal pressure Then the risk of gastrointestinal hemorrhage is decreased which provides an opportunity for system therapy Studies have proven that early transjugular intrahepatic portosystemic shunt TIPS with 72 hours after acute variceal bleeding is effective for cirrhosis induced portal hypertension However the PVTT induced portal hypertension still needs clinical evidence In this study the investigators explore the early TIPS for advanced hepatocellular carcinoma with main trunk portal vein tumor thrombus induced acute variceal bleeding The investigators aim to added clinical evidence for this subtype of advanced HCC
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None